MedTrace Logo

Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy

NCT07602127 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-05-22

No results posted yet for this study

Summary

This is AGX-08's safety, tolerability, and efficacy in Geographic Atrophy first-in-human study. This trial is meant to evaluate the safety and efficacy of AGX-08 in Geographic Atrophy patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.

Conditions

Interventions

DRUG

AGX-08-L

rAAV2.AG-eNCRV intravitreal injection of low dose

DRUG

AGX-08-M

rAAV2.AG-eNCRV intravitreal injection of middle dose

DRUG

AGX-08-H

rAAV2.AG-eNCRV intravitreal injection of high dose

PROCEDURE

AGX-08-S

sham intravitreal injection of AGX-08 (not actual injection)

Sponsors & Collaborators

  • Zhongmou Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2028-12-30
Completion
2029-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07602127 on ClinicalTrials.gov